Ca 2+-sensitisers - A promising option to treat heart failure?

Cardiovascular Drugs and Therapy

Volumn 19, Issue 6, 2005, Pages 423-428

  Brixius, Klara ^a,b   Hoyer, Heike Katharina ^a   Schwinger, Robert H G ^a,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^c Klinikum Weiden   (Germany)

Author keywords

Ca 2+ sensitiser; Heart failure; Levosimendan; Myofilaments; Pimobendan

Indexed keywords

1,3,5,6 TETRAHYDRO 5 METHYL 6 PHENYL 3,6 METHANO 1,5 BENZODIAZOCINE 2,4 DIONE; 4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ACTIN; CALCIUM CHANNEL L TYPE; CALCIUM ION; CALCIUM SENSITIZER; CATECHOLAMINE; CYCLIC AMP; INOTROPIC AGENT; LEVOSIMENDAN; MYOSIN; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PIMOBENDAN; POTASSIUM CHANNEL; TROPOMYOSIN; TROPONIN; UNCLASSIFIED DRUG; CALCIUM; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACIDOSIS; CALCIUM BINDING; CALCIUM CELL LEVEL; CALCIUM CURRENT; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE RELAXATION; HUMAN; LONG QT SYNDROME; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; STUNNED HEART MUSCLE; VASODILATATION; CONGESTIVE HEART FAILURE; METABOLISM;

CALCIUM; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; PYRIDAZINES;

EID: 32444439236     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-005-6128-7     Document Type: Review

References (41)

1. Iwai-Kanai E, Hasegawa K. Intracellular signaling pathways for norepinephrine- and endothelin-1-mediated regulation of myocardial cell apoptosis. Mol Cell Biochem 2004;259:163-168.
2. Pinelli A, Trivulzio S, Tomasoni L, et al. Myocardial infarction non-invasively induced in rabbits by administering isoproterenol and vasopressin: protective effects exerted by verapamil. Fundam Clin Pharmacol 2004;18:657-667.
3. London B, Baker LC, Lee JS, et al. Calcium-dependent arrhythmias in transgenic mice with heart failure. Am J Physiol 2003;284:H431-H441.
4. 2+ sensitizers EMD 57033 and CGP 48506 on cross-bridge cycling in human myocardium. J Pharmacol Exp Ther 2000;295:1284-1290.
5. Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992;85:1046-1055.
6. Gordon AM, Homsher E, Regnier M. Regulation of contraction in striated muscle. Physiol Rev 2000;80:853-924.
7. 2+ sensitizers-update 2001. Cardiovasc Drugs Ther 2001;15:397-403.
8. Hagemeijer F, Brand HJ, van Mechelen R. Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1989;63:571-576.
9. 2+ current and developed tension in guinea-pig ventricular myocytes and papillary muscle: comparison with IBMX, milrinone, and cilostazol. Cardiovasc Drugs Ther 1999;13:105-113.
10. Westfall MV, Wahler GM, Fujino K, Solaro RJ. Electrophysiological actions of the pimobendan metabolite, UD-CG 212 Cl, in guinea pig myocardium. J Pharmacol Exp Ther 1992;260:58-63.
11. + channels in vascular smooth-muscle cells. J Cardiovasc Pharmacol 1997;30:739-743.
12. Lubsen J, Just H, Hjalmarsson AC, La Framboise D, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996;76:223-231.
13. The EPOCH Study Group. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure (EPOCH study). Circ J 2002;66:149-157.
14. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-1866.
15. 2+ sensitizer levosimendan in human myocardium. Am J Physiol 2002;282:H131-H137.
16. 2+ transients in the human heart. J Appl Physiol 1997;83:652-660.
17. Lubbe WF, Podzuweit T, Opie LH. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol 1992;19:1622-1633.
18. Szilagyi S, Pollesello P, Levijoki J, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 2004;486:67-74.
19. Boknik P, Neumann J, Kaspareit G, et al. Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exp Ther 1997;280:277-283.
20. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995;77:107-113.
21. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998;98:2141-2147.
22. i in guinea-pig isolated ventricular myocytes. Eur J Pharmacol 1997;339:97-100.
23. 2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 1998;30:1115-1128.
24. 2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor. Am Heart J 1997;133:283-289.
25. Shahid M, Nicholson CD. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram. Naunyn Schmiedebergs Arch Pharmacol 1990;342:698-705.
26. Verde I, Vandecasteele G, Lezoualch F, Fischmeister R. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes. Br J Pharmacol 1999;127:65-74.
27. Pataricza J, Krassoi I, Hohn J, Kun A, Papp JG. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs The 2003;17:115-121.
28. Sundberg S, Lilleberg J, Nieminen MS, Lehtonen L. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol 1995;75:1061-1066.
29. Du Toit EF, Muller CA, McCarthy J, Opie LH. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 1999;290:505-514.
30. Labriola C, Siro-Brigiani M, Carrata F, Santangelo E, Amantea B. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 2004;42:204-211.
31. Poder P, Eha J, Sundberg S, et al. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study. J Clin Pharmacol 2004;44:1143-1150.
32. Maury P, Baixas C, Roncalli J, et al. Resumption of atrioventricular conduction by levosimendan after radiofrequency ablation of the AV node. Pacing Clin Electrophysiol 2004;27:1314-1316.
33. Usta C, Puddu PE, Papalia U, et al. Comparision of the inotropic effects of levosimendan, rolipram, and dobutamine on human atrial trabeculae. J Cardiovasc Pharmacol 2004;44:622-625.
34. Lilleberg J, Ylonen V, Lehtonen L, Toivonen L. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J 2004;38:80-84.
35. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003;41:997-1003.
36. Follath F. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial. Ital Heart J 2003;4 Suppl 2:34S-38S.
37. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
38. Shakar SF, Abraham WT, Gilbert EM, et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998;31:1336-1340.
39. 2+ sensitization with a new cardiotonic agent, MCI-154, on diseased human hearts. Cardiovasc Res 1995;30:915-922.
40. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002;23:1422-1432.
41. Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004;6:501-508.